Stay updated on Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T11:03:53.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4 and has changed the date from 2025-03-25 to 2025-02-25.
    Difference
    0.6%
    Check dated 2025-04-09T05:17:49.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    26 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    The page has updated the reference to Seagen, clarifying its relationship as a subsidiary of Pfizer, and has changed a date from November 13, 2024, to February 25, 2025.
    Difference
    3%
    Check dated 2025-03-03T23:06:42.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T20:16:14.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    6%
    Check dated 2025-02-10T09:31:20.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T05:34:27.000Z thumbnail image

Stay in the know with updates to Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib vs. Placebo with T-DM1 in HER2+ Breast Cancer Clinical Trial page.